Kymera Investor Day Presentation Deck

Ex Vivo Inhibition of 9 Disease-Relevant Cytokines, Day 7-14 Results through MAD3 Showed Dose-Dependent Effect Tracking with Extent of Monocyte IRAK4 Degradation Pbo 200 50 mg QD 100 -50 -100 100 mg QD IFNY IL10 IL6 IL8 116% -39% 15% IL10 IL12 IL17 IL23 357% 292% -5% -10% 880% -11% 72% 91% LPS -27% 4% 81% 2% -2% -48% -63% -54% -46% -49% -42% -28% -58% TNFa 70% 40% -57% 50 mg QD: 93-95% PBMC degradation at Day 7-10; 87-90% Monocyte degradation at Day 7-14 100 mg QD: 97-98% PBMC degradation at Day 7-10; 92-93% Monocyte degradation at Day 7-14 KYMERA ©2021 KYMERA THERAPEUTICS, INC. Placebo (n = 9) 50 mg QD (n = 9) 100 mg QD (n = 8-9*) Pbo 50 mg QD 100 mg QD 200 100 0 -50 -100 IFNY >500% -62% -85% KYMERA R&D DAY - December 16th, 2021 H IL1B 15% -59% -68% IL6 35% -18% -53% +4 IL8 -5% -28% -32% IL10 -23% 2% -50% IL12 3% -58% -72% R848 IL17 107% -24% -46% TNFa -7% -21% -59% *n=8 for LPS, n=9 for R848 Mean values > 200% have been replaced by 200 for visualization purposes PAGE 40

View entire presentation